• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Xylo Technologies Ltd.

    3/4/25 4:00:11 PM ET
    $XYLO
    Medical/Dental Instruments
    Health Care
    Get the next $XYLO alert in real time by email
    6-K 1 ea0233085-6k_xylo.htm REPORT OF FOREIGN PRIVATE ISSUER

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of March 2025

     

    Commission File Number 001-37381

     

    XYLO TECHNOLOGIES LTD.

    (Translation of registrant’s name into English)

     

    10 HaNechoshet Street, Tel-Aviv 6971072, Israel

    (Address of principal executive offices)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

     

    Form 20-F ☒             Form 40-F ☐

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    Xylo Technologies Ltd. (the “Company”), hereby announces that L.I.A Pure Capital Ltd. (“Pure Capital”), which currently holds 8.87% of the Company’s issued and outstanding share capital (per a Schedule 13D filed by Pure Capital with the Securities and Exchange Commission (the “SEC”) on February 18, 2025), after conducting discussions with the Company, has filed an amendment to its request in the Tel Aviv District Court (Economic Division) (the “Court”) to convene a special general meeting of the Company’s shareholders (the “Amended Request”), to approve an arrangement between the Company and its shareholders in accordance with Section 350 of the Israeli Companies Law, 5799-1999 (the “Arrangement”).

     

    The Amended Request increases Pure Capital’s proposal for the acquisition of the remaining 91.13% of the Company’s issued and outstanding share capital to an updated purchase price of $0.13125 per ordinary share of the Company (or $5.25 per American Depositary Share (“ADS”)) as opposed to the previous proposed purchase price of $0.0925 per ordinary share of the Company (or $3.70 per ADS). The Amended Request further clarifies, subject to shareholder approval of the Arrangement, that (i) Pure Capital commits to purchase restricted share units granted to the Company’s employees, officers and directors that are subject to acceleration upon a change of control; and (ii) the Company will purchase customary run-off insurance as of the date the Arrangement becomes effective.

     

    The Court has given the Company until March 12, 2025, to submit a response to the Amended Request.  

     

    Forward Looking Statement

     

    This Report of Foreign Private Issuer contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. Because such statements deal with future events and are based on the Company’s current expectations, they are subject to various risks and uncertainties, and actual results, performance or achievements of the Company could differ materially from those described in or implied by the statements in this Report of Foreign Private Issuer on Form 6-K. For example, the Company cannot guarantee the Court will approve the Amended Request, that if the Court approves the Amended Request that it will receive shareholder approval and that if the Arrangement receives shareholder approval that it will be approved by the Court.

     

    The forward-looking statements contained or implied in this Report of Foreign Private Issuer on Form 6-K are subject to other risks and uncertainties, including those discussed in any filings with the SEC. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

     

    1

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      XYLO TECHNOLOGIES LTD.
         
    Date: March 4, 2025 By: /s/ Tali Dinar
        Tali Dinar
        Chief Financial Officer

     

     

    2

     

     

    Get the next $XYLO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $XYLO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $XYLO
    SEC Filings

    View All

    SEC Form EFFECT filed by Xylo Technologies Ltd.

    EFFECT - XYLO TECHNOLOGIES LTD (0001618500) (Filer)

    8/26/25 12:15:01 AM ET
    $XYLO
    Medical/Dental Instruments
    Health Care

    SEC Form 15-12G filed by Xylo Technologies Ltd.

    15-12G - XYLO TECHNOLOGIES LTD (0001618500) (Filer)

    8/22/25 4:00:04 PM ET
    $XYLO
    Medical/Dental Instruments
    Health Care

    SEC Form 25-NSE filed by Xylo Technologies Ltd.

    25-NSE - XYLO TECHNOLOGIES LTD (0001618500) (Subject)

    8/22/25 9:06:32 AM ET
    $XYLO
    Medical/Dental Instruments
    Health Care

    $XYLO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Xylo Technologies: Viewbix Shares to Begin Trading on Nasdaq

    TEL AVIV, Israel, June 05, 2025 (GLOBE NEWSWIRE) -- Xylo Technologies Ltd. (NASDAQ:XYLO) ("Xylo" or the "Company"), a technology-based company engaged in advanced innovative technologies, announced today that Viewbix Inc. (NASDAQ:VBIX), a global developer of ad-tech innovative technologies, has received approval for its shares of common stock to be listed on the Nasdaq Capital Market. Viewbix, in which Xylo holds an indirect stake through its 45.74% ownership in Gix Internet Ltd. ("Gix Internet"), which in turn owns 2,818,585 common shares representing 42.58% of Viewbix, expects its shares to commence trading on Nasdaq under the symbol "VBIX" on or about June 5, 2025, subject to continued

    6/5/25 9:21:00 AM ET
    $MDGS
    $XYLO
    Medical/Dental Instruments
    Health Care

    Xylo Technologies: Charging Robotics Successfully Installs Wireless EV Charging System in Automatic Parking Facility

    TEL AVIV, Israel, April 30, 2025 (GLOBE NEWSWIRE) -- Xylo Technologies Ltd. (NASDAQ:XYLO) ("Xylo" or the "Company"), a technology-based company engaged in advanced innovative technologies, announced today that Charging Robotics, Inc. (OTC:CHEV) ("Charging Robotics"), a Delaware corporation (62.22% owned by Xylo), has successfully installed a system for wireless charging of electric vehicles with a leading supplier of robotic parking facilities.  Following the installation, the system successfully demonstrated the ability to wirelessly transfer power.  The system is intended to be used for charging electric vehicles ("EVs") while reporting charge data to the cloud and managing the charging

    4/30/25 9:12:00 AM ET
    $MDGS
    $XYLO
    Medical/Dental Instruments
    Health Care

    Xylo Technologies: Revoltz Secures First Institutional Client for PORTO EV Logistics Deployment

    TEL AVIV, Israel, April 29, 2025 (GLOBE NEWSWIRE) -- Xylo Technologies Ltd. (NASDAQ:XYLO) ("Xylo" or the "Company"), a technology-based company engaged in advanced innovative technologies, announced today that Revoltz Ltd. ("Revoltz"), which is 19.9% held by Charging Robotics, Inc. (OTC:CHEV) ("Charging Robotics"), a Delaware corporation quoted on the OTC Market (62.22% owned by Xylo), has secured its first institutional client for the PORTO EV, Revoltz's flagship electric micro-vehicle designed for last-mile logistics. The new order marks a significant step in Revoltz's commercial expansion strategy, transitioning from individual sales into larger fleet deployments. The institutional cus

    4/29/25 6:34:08 AM ET
    $MDGS
    $XYLO
    Medical/Dental Instruments
    Health Care